about
New macrocyclic analogs of the natural histone deacetylase inhibitor FK228; design, synthesis and preliminary biological evaluation.miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis.[1,2]Oxazolo[5,4-e]isoindoles as promising tubulin polymerization inhibitors.Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma.Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.Maspin influences response to doxorubicin by changing the tumor microenvironment organization.Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat.Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
P50
Q38611193-FF718419-66BC-4183-A72B-E9262EAEF682Q38713064-0A18E49E-3146-47BE-8358-2062A4F55C04Q38745258-B1A329A2-0B93-49B6-90DA-7A61A6E4C0F5Q38757544-BC3ED215-7276-4E4B-81B1-5A85DB8B7D30Q38918627-3E65D18A-43BF-4F55-B094-C6D5E5263430Q39042587-D36B44DA-A086-481E-8B0A-1CE78674093CQ39044610-E69862C5-51B3-4E08-8FB4-9588F75372AAQ39054890-6739950C-6C6F-4D5A-B94C-F60D4ADE9FB0Q39062271-95F5A5E6-998E-4540-8FEA-F139079573DAQ39184529-C46DE2E0-2AC2-4987-BEBA-AAD685F0CB8FQ40296990-006FA653-8569-477D-8D4A-FDD0FA4288C3Q44134106-2DFBD33A-3B83-4724-84D6-3596C25D09FFQ45345506-02688F22-2BA5-4E07-890F-853A4E492B7AQ48089220-B0B3B305-0DCF-476A-B40A-67173298A0EFQ51694181-DE150A1E-9C56-40CC-8170-D80AE6AFF8ABQ54515616-2564A62F-9A07-4033-848F-7C73F0E578ED
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Denis Cominetti
@ast
Denis Cominetti
@en
Denis Cominetti
@es
Denis Cominetti
@nl
Denis Cominetti
@sl
type
label
Denis Cominetti
@ast
Denis Cominetti
@en
Denis Cominetti
@es
Denis Cominetti
@nl
Denis Cominetti
@sl
prefLabel
Denis Cominetti
@ast
Denis Cominetti
@en
Denis Cominetti
@es
Denis Cominetti
@nl
Denis Cominetti
@sl
P1053
K-7581-2016
P106
P1153
55206008000
P21
P31
P3829
P496
0000-0003-1324-6432